川芎嗪对老年闭塞性动脉硬化症血瘀证患者CD62p基因表达的调控

Control of ligustrazine on CD62p gene of old patients with arteriosclerosis obliterans blood statsis syndrome

目的观察川芎嗪对老年闭塞性动脉硬化症血瘀证患者CD62p基因表达的影响,从基因水平探索川芎嗪治疗作用的微观实质。方法以病证结合方式,严格按照诊断标准选取160例老年闭塞性动脉硬化症血瘀证和非血瘀证患者,给予川芎嗪治疗。用流式细胞技术,观察治疗前后患者CD62p基因的表达,并以健康人为对照。结果血小板CD62p的表达水平治疗前为(4.35±1.91)%,治疗后下降为(2.98±1.05)%(P<0.05)。血小板CD62p的表达水平气虚血瘀组(5.24±2.92)%,气滞血瘀组(8.17±2.05)%,阴虚血瘀组(5.59±2.78)%,痰浊血瘀组(5.78±2.85)%,较正常对照组〔(2.08±1.07)%〕显著升高(P<0.01)。结论川芎嗪可有效抑制CD62p基因的异常表达。

Objective To observe the effect of ligustrazine on CD62p gene of old patients with arteriosclerosis obliterans （ASO） blood statsis syndrome （BSS） and explore the micro-essence action of ligustrazine at the gene level. Methods According to diagnosis stand- ard strictly, 160 old ASO patients with and without BSS were selected by means of combination of disease and symptoms and treated with ligustrazine. The expressions of CD62p gene from patients were measured before and after treatment, and then were compared with healthy persons. Results The expression of CD62p was （4. 35 ± 1.91 ） % before treatment and was （2.98 ±1.05） % after treatment, and there was obvious difference（P 〈0. 05 ）. The expression of CD62p of BSS due to qi deficiency, qi block, yin deficiency and phlegm was （5.24± 2. 92） % , （8. 17 ± 2. 05） % , （5.59 ± 2. 78） % and （5.78 ± 2. 85 ） % respectively, which were all higher than that of normal control group [ （2. 08 ± 1.07 ） %] （ P 〈 0.01 ）. Conclusions Ligustrazine can inhibit the abnormal expression of CD62p efficiently.